# PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma

> **NCT02492815** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1773 (actual)

## Conditions studied

- Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02492815
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-31
- **Primary completion:** 2016-04-30
- **Final completion:** 2016-04-30
- **Target enrollment:** 1773 (ACTUAL)
- **Last updated:** 2019-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02492815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02492815, "PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02492815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*